Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-19
DOI
10.1007/s00262-021-02925-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.
- (2020) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
- (2019) Paul Nghiem et al. JOURNAL OF CLINICAL ONCOLOGY
- Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
- (2019) Sandra P. D’Angelo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
- (2019) Y J L Jansen et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma
- (2019) Mahtab Samimi AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma
- (2019) Rocio Garcia‐Carbonero et al. ONCOLOGIST
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- (2018) Caroline Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy for Merkel cell carcinoma: a turning point in patient care
- (2018) Isaac S. Chan et al. Journal for ImmunoTherapy of Cancer
- Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
- (2018) A. Bernard-Tessier et al. EUROPEAN JOURNAL OF CANCER
- Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
- (2018) Alice Indini et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
- (2017) C Lance Cowey et al. Future Oncology
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Reinduction of PD1-inhibitor therapy
- (2017) Hanna Blasig et al. MELANOMA RESEARCH
- Merkel cell carcinoma
- (2017) Jürgen C. Becker et al. Nature Reviews Disease Primers
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started